Tags

Type your tag names separated by a space and hit enter

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.
Mult Scler. 2004 Aug; 10(4):434-41.MS

Abstract

The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three centres, recruiting 160 outpatients with MS experiencing significant problems from at least one of the following: spasticity, spasms, bladder problems, tremor or pain. The interventions were oromucosal sprays of matched placebo, or whole plant CBME containing equal amounts of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) at a dose of 2.5-120 mg of each daily, in divided doses. The primary outcome measure was a Visual Analogue Scale (VAS) score for each patient's most troublesome symptom. Additional measures included VAS scores of other symptoms, and measures of disability, cognition, mood, sleep and fatigue. Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to 48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P =0.001). There were no significant adverse effects on cognition or mood and intoxication was generally mild.

Authors+Show Affiliations

Oxford Centre for Enablement, Windmill Road, Oxford OX3 7LD, UK. derick.wade@dsl.pipex.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15327042

Citation

Wade, Derick T., et al. "Do Cannabis-based Medicinal Extracts Have General or Specific Effects On Symptoms in Multiple Sclerosis? a Double-blind, Randomized, Placebo-controlled Study On 160 Patients." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 10, no. 4, 2004, pp. 434-41.
Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434-41.
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Multiple Sclerosis (Houndmills, Basingstoke, England), 10(4), 434-41.
Wade DT, et al. Do Cannabis-based Medicinal Extracts Have General or Specific Effects On Symptoms in Multiple Sclerosis? a Double-blind, Randomized, Placebo-controlled Study On 160 Patients. Mult Scler. 2004;10(4):434-41. PubMed PMID: 15327042.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. AU - Wade,Derick T, AU - Makela,Petra, AU - Robson,Philip, AU - House,Heather, AU - Bateman,Cynthia, PY - 2004/8/26/pubmed PY - 2005/2/9/medline PY - 2004/8/26/entrez SP - 434 EP - 41 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 10 IS - 4 N2 - The objective was to determine whether a cannabis-based medicinal extract (CBME) benefits a range of symptoms due to multiple sclerosis (MS). A parallel group, double-blind, randomized, placebo-controlled study was undertaken in three centres, recruiting 160 outpatients with MS experiencing significant problems from at least one of the following: spasticity, spasms, bladder problems, tremor or pain. The interventions were oromucosal sprays of matched placebo, or whole plant CBME containing equal amounts of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) at a dose of 2.5-120 mg of each daily, in divided doses. The primary outcome measure was a Visual Analogue Scale (VAS) score for each patient's most troublesome symptom. Additional measures included VAS scores of other symptoms, and measures of disability, cognition, mood, sleep and fatigue. Following CBME the primary symptom score reduced from mean (SE) 74.36 (11.1) to 48.89 (22.0) following CBME and from 74.31 (12.5) to 54.79 (26.3) following placebo [ns]. Spasticity VAS scores were significantly reduced by CBME (Sativex) in comparison with placebo (P =0.001). There were no significant adverse effects on cognition or mood and intoxication was generally mild. SN - 1352-4585 UR - https://www.unboundmedicine.com/medline/citation/15327042/Do_cannabis_based_medicinal_extracts_have_general_or_specific_effects_on_symptoms_in_multiple_sclerosis_A_double_blind_randomized_placebo_controlled_study_on_160_patients_ L2 - https://journals.sagepub.com/doi/10.1191/1352458504ms1082oa?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -